S1 Going Nuts Over Food Allergies: A Quality Improvement Project
Danan et al

S2 Video Procedural Training Series as a means of Onboarding to an Allergy Entrustable Professional Activity (EPA)
Kohli et al

S3 From Sweet to Swollen: The Unexpected Link Between Soursop and ACE Inhibition Leading to Acute Angioedema
Chen et al

S4 Safety of Dupixent (Dupilumab) Use During Pregnancy: A Composite Evaluation of Pregnancy Outcomes
Ventura and Clayton

S5 Provider perspectives on the iREACH peanut allergy prevention intervention: A qualitative analysis using a rapid framework analysis approach
Ibrahim et al

S6 Atypical Carcinoid Presenting as Reversible Obstruction with Wheeze
Soto and Barberis

S7

S8 COMFORT Toddlers: phase 3 supplemental safety study of epicutaneous immunotherapy in 1-through-3-year-old peanut-allergic toddlers
Funded by DBV Technologies

S9 Time to End of Progression of Hereditary Angioedema Attacks Treated with Sebetralstat
Funded by KalVista Pharmaceuticals

S10 On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Older Adults: Interim Analysis from KONFIDENT-S
Funded by KalVista Pharmaceuticals

S11 Dupilumab Induces Clinical Remission in Children With Uncontrolled, Effectiveness of Sebetralstat for Severe or Very Severe Hereditary Angioedema Attacks in KONFIDENT-S
Funded by KalVista Pharmaceuticals

S12 Long-Term Prophylaxis Compliance and Healthcare Resource Utilization in Hereditary Angioedema: A Claims Database Analysis
Funded by KalVista Pharmaceuticals

S13 Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme
Funded by GSK [GSK ID: MEA116841/NCT03298061]

S14 Real-World Mepolizumab Use for Chronic Rhinosinusitis with Nasal Polyps and Severe Asthma Improves Clinical/Economic Outcomes
Funded by GSK [218957]

S15 Mepolizumab Reduces Systemic Corticosteroid (SCS)-Related Toxicities Compared to Chronic SCS Use in Patients with EGPA
Funded by GSK (221046)

S16 Rocatinlimab Significantly Improved Clinical Signs and Symptoms by Targeting OX40R+ T cells in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ROCKET-Horizon Trial
Funded by Amgen Inc. and Kyowa Kirin Co., Ltd.

S17 Reduction in Asthma Exacerbations Following Initiation of Benralizumab Among Medicare Beneficiaries: Results from the ZEPHYR-5 Study
Funded by AstraZeneca

S18 Lung Function Improvement in Patients with Uncontrolled, Moderate-to-severe Asthma Treated with Benralizumab: A New, Retrospective Analysis of the Pooled SIROCCO and CALIMA Studies
Funded by AstraZeneca

S19 Lebrikizumab Improves Atopic Dermatitis in Adult and Adolescent Patients with Skin of Color: 16-week Results from the ADmirable Study
Funded by Dermira, subsidiary of Eli Lilly and Company

S20 Maintenance of Lebrikizumab Efficacy in Patients With Moderate-To-Severe Atopic Dermatitis and Atopic Comorbidities
Funded by Dermira, subsidiary of Eli Lilly and Company

S21 Long-term Efficacy and Safety of Lebrikizumab is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up To 3 Years From ADjoin
Funded by Dermira, subsidiary of Eli Lilly and Company

S22 Key Treatment Attributes and Preferences of Allergists and Dermatologists for Moderate-To-Severe Atopic Dermatitis: Results from a US-Based Real-World, Cross-Sectional Study
Funded by: Eli Lilly and Compny

S23 Albuterol-Budesonide Treatment in Acute Airway Obstruction: Patient Selection for the ALTA Study
Funded by: AstraZeneca

S24 Performance of the Pediatric Asthma Impairment and Risk Questionnaire (Peds-AIRQ) in Assessing Control for Children with Asthma Aged 5 to 11 Years
Funded by AstraZeneca

S25 Two-Year Efficacy and Safety of Benralizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis
Funded by AstraZeneca

S26 Dupilumab is Efficacious in Children (Aged 1 to <12 Years) With Eosinophilic Esophagitis Regardless of Prior History of Comorbidities
Funded by Sanofi and Regeneron Pharmaceuticals Inc.

S27 Dupilumab improves histologic, symptomatic, and endoscopic outcomes in children with eosinophilic esophagitis in the EoE KIDS study, regardless of history of elimination diet or concomitant food allergy
Funded by Sanofi and Regeneron Pharmaceuticals Inc.

S28 Dupilumab Efficacy in Pooled LIBERTY-CSU CUPID Study A and Study C Regardless of Baseline Total Serum IgE Levels
Funded by Sanofi and Regeneron Pharmaceuticals Inc. (NCT04180488)

S29 Dupilumab Provides Early and Sustained Improvement in Itch in Patients With Chronic Spontaneous Urticaria: Pooled Results From LIBERTY-CSU CUPID Study A and Study C
Funded by Sanofi and Regeneron Pharmaceuticals Inc. (NCT04180488)

S30 Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria: Pooled Results From LIBERTY-CSU CUPID Study A and Study C
Funded by Sanofi and Regeneron Pharmaceuticals Inc. (NCT04180488)

S31 Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib
Funded by Cogent Biosciences

S32 Updated Efficacy and Safety Results of Patients Receiving Selected 100 mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis
Funded by Cogent Biosciences

S33 Mepolizumab Decreases Exacerbations in Patients with Asthma and Chronic Obstructive Pulmonary Disease: US Claims Data
Funded by GSK [222359]

S34 Benefit of Early Versus Delayed Intervention with Mepolizumab in Patients with Severe Uncontrolled Asthma (SUA): A Retrospective Cohort Study
Funded by GSK [221029]

S35 Mepolizumab Improves and Sustains Clinical Benefits in Patients with Severe Asthma, Independent of IgE and FeNO at Baseline: Real-World Analysis of REALITI-A Results at 2 Years
Funded by GSK (204710)

S36 Real-World Persistence to Biologic Therapies and its Impact on Outcomes in Patients with Asthma
Funded by GSK (223657)

S37 Correlation between Subjective and Objective Disease Control in Hereditary Angioedema: Association between the Angioedema Control Test and Attack Rate
Funded by Ionis Pharmaceuticals

S38 Hereditary Angioedema Disease Control After Switching To Donidalorsen From Prior Long-Term Prophylaxis: Results From The OASISplus Open-Label Extension Study
Funded by Ionis Pharmaceuticals

S39 Epinephrine Delivered via Sublingual Film (Anaphylm™) Elicits Rapid and Consistent Pharmacokinetic and Pharmacodynamic Responses
Funded by Aquestive Therapeutics, Inc

S40 The Physicochemical Properties of Anaphylm™ Under Extreme Temperatures and Real-World Conditions
Funded by Aquestive Therapeutics, Inc

S41 Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Funding by Arcutis Biotherapeutics, Inc.

S42 Patient-reported outcomes and family impact with roflumilast cream 0.15% in atopic dermatitis: pooled results from phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials
Funding by Arcutis Biotherapeutics, Inc.

S43 Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients aged 2– 5 years with mild-to-moderate atopic dermatitis: a phase 3 randomized controlled trial (INTEGUMENT PED)
Funded by Arcutis Biotherapeutics, Inc

S44 HAE Attack Rates in Pediatric Patients 2 to <12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P
Funded by BioCryst Pharmaceuticals, Inc.

S45 The Use of neffy (Epinephrine Nasal Spray) to Treat Anaphylaxis During an Oral Food Challenge
Funded by ARS Pharmaceuticals

S46 Successful usage of intranasal epinephrine during in-office anaphylaxis, a case series of three pediatric patients in real-world setting
Funded by ARS Pharmaceuticals